Oncologists reveal why breakthrough cancer drugs still stall—referral gaps, payer delays, caregiver needs, and pharmacy bottlenecks reshape access across tumor types.
|Peer-Reviewed|December 23, 2020
- January 2021
- Volume 27
- Issue 1
Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Advertisement
Articles in this issue
almost 6 years ago
ASH 2020: Clinical Updatesalmost 6 years ago
ASH 2020: COVID-19 and Hematologyalmost 6 years ago
ASH 2020: CAR T-Cell Therapy Updatesalmost 6 years ago
ASH 2020: The Next Wavealmost 6 years ago
2020 SABCS: Topics in Precision OncologyAdvertisement
Related to this article
Advertisement
Advertisement
Trending on AJMC
1
Unanswered Questions in First- and Second-Line mCRC Care
2
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
3
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
4
GOLD COPD Conference Turns to Earlier Diagnosis and Proactive Care
5